FILTER

Refine your search with the following facets to narrow down your results.

25,662 Current news

Biogenerics Market Poised for Launch as Blockbuster Patents Expire

07-Sep-2005 - The biogenerics market, long hindered by a lack of regulatory framework, is now showing signs of development. With patents for the earliest biopharmaceuticals to reach the market beginning to expire, the first biogeneric products are anticipated to reach the regulated markets in North America and ...

anaemia biopharmaceuticals clinical trials +8

Bayer CropScience: Sales of new products should rise to EUR 2 billion

07-Sep-2005 - Bayer CropScience AG has substantially raised its forecast for annual sales of crop protection products containing new active ingredients, to EUR 2 billion. Since 2000, Bayer CropScience has introduced 16 new substances, which already posted revenues of EUR 517 million in the first half of 2005. ...

Bayer cotton crop protection +6

Casting a wide net to fight coronaviruses

07-Sep-2005 - Coronaviruses - the family of viruses that causes the common cold - gained widespread recognition when the deadly severe acute respiratory syndrome, familiarly known as SARS, killed at least 800 people in 2003. Research efforts to design antiviral agents to combat coronaviruses intensified after ...

bases Binding Site clinical trials +8

Arakis commences Phase IIB trial for rheumatoid arthritis drug

07-Sep-2005 - Sosei Co. Ltd. announcee that its wholly-owned subsidiary Arakis Ltd ("Arakis"), has commenced a Phase IIb dose ranging study of AD 452, a novel, small molecule, disease modifying anti-rheumatic drug (DMARD), designed to reduce joint inflammation and destruction, pain, and preserve mobility. The ...

arthritis inflammation methotrexate +5

Amgen Announces Initiation of Phase 3 Trial to Evaluate the Impact of Treating Anemia with Darbepoetin Alfa

06-Sep-2005 - Amgen announced that it will initiate a Phase 3 randomized, placebo-controlled, double-blind, multicenter, multi-national trial to evaluate the effect of anemia treatment with darbepoetin alfa on morbidity and mortality in patients with heart failure. "Amgen's decision to proceed with its Phase ...

Amgen anemia darbepoetin alfa +1

Affymetrix Microarrays Uncover Genetic Mutations in Embryonic Stem Cells Approved for Federally-Funded Research

06-Sep-2005 - Affymetrix Inc. announced that a research group led by scientists at Johns Hopkins School of Medicine and the NIH used Affymetrix GeneChip(R) microarrays to discover that eight of the stem cell lines approved for federally-funded research have mutated, raising concern about the use of the ...

Affymetrix cell lines embryonic stem cells +10

Tracleer Excellence Post Marketing Surveillance Programme (TRAX PMSTM) confirms long-term safety profile

06-Sep-2005 - Actelion Ltd announced that two abstracts presented at the European Society of Cardiology (ESC) conference confirm the long-term safety profile of Tracleer® (bosentan) in treating pulmonary arterial hypertension (PAH). Both abstracts comprise data from TRAX PMSTM, which was set up in the EU in ...

Actelion cardiology cardiovascular diseases +2

New Additions to American Seeds, Inc. Accelerate Growth in Monsanto's Regional Seed Company Approach

06-Sep-2005 - Monsanto Company's American Seeds, Inc. (ASI) subsidiary announced it made five key strategic additions to its family of regional seed companies. The additions are expected to further bolster ASI's ability to help serve farmer-customers with a technology-rich, locally-oriented business model. In ...

hybrids Monsanto

A new link between stem cells and tumors

06-Sep-2005 - Scientists at the European Molecular Biology Laboratory [EMBL] in Heidelberg and the Institute of Biomedical Research of the Parc Científic de Bar de Barcelona [IRB-PCB] have now added key evidence to claims that some types of cancer originate with defects in stem cells. The study shows that if ...

Bio-Medical Research CAS cell division +9

BioInformatics survey: Affymetrix Dominates DNA Microarrays Market

05-Sep-2005 - A recent survey reveals that Affymetrix continues to be the dominant supplier in the DNA microarray market, which includes DNA microarrays, microarray scanners, and data analysis software. The survey found that 81% of researchers use commercial DNA microarrays, either exclusively or in addition ...

Affymetrix Agilent Technologies Applied Biosystems +8